Zymeworks Revenue 2016-2022 | ZYME

Zymeworks revenue from 2016 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Zymeworks Annual Revenue
(Millions of US $)
2021 $27
2020 $39
2019 $30
2018 $53
2017 $52
2016 $11
2015 $10
Zymeworks Quarterly Revenue
(Millions of US $)
2022-06-30 $5
2022-03-31 $2
2021-12-31 $20
2021-09-30 $4
2021-06-30 $2
2021-03-31 $1
2020-12-31 $16
2020-09-30 $3
2020-06-30 $12
2020-03-31 $8
2019-12-31 $2
2019-09-30 $8
2019-06-30 $8
2019-03-31 $12
2018-12-31 $29
2018-09-30 $2
2018-06-30 $22
2018-03-31 $0
2017-12-31 $50
2017-09-30 $0
2017-06-30 $1
2017-03-31 $0
2016-12-31 $2
2016-09-30 $2
2016-06-30 $6
2016-03-31 $0
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.494B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.477B 10.28
GSK (GSK) United Kingdom $69.125B 8.67
Bio-Rad Laboratories (BIO.B) United States $11.666B 27.68
QIAGEN (QGEN) Netherlands $11.120B 18.98
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.592B 0.00
Arcus Biosciences (RCUS) United States $1.934B 29.03
Biohaven (BHVN) United States $1.080B 0.00
Emergent Biosolutions (EBS) United States $0.594B 4.67
ADC Therapeutics SA (ADCT) Switzerland $0.276B 0.00
Enzo Biochem (ENZ) United States $0.095B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00